Weir M R, Peppler R, Gomolka D, Handwerger B S
Division of Nephrology, University of Maryland Hospital, Baltimore 21201.
Immunopharmacology. 1993 Jan-Feb;25(1):75-82. doi: 10.1016/0162-3109(93)90032-l.
An important role of transmembrane flux of calcium in lymphocyte activation has been previously demonstrated. Herein, we demonstrate that the calcium channel blockers verapamil and isradipine are able to inhibit in a concentration-dependent manner 3H-thymidine incorporation into DNA in phytohemagglutinin (PHA)-stimulated human peripheral blood mononuclear cells (PBMC). However, verapamil and isradipine diminish PHA-stimulated thymidine incorporation into DNA to the same extent whether they are added at the beginning of culture or 4 h prior to completion of a 72-h culture. Thus, 3H-thymidine incorporation into DNA in the presence of verapamil or isradipine is not a valid measure of mitogen-induced lymphocyte proliferation. Similarly, verapamil and isradipine also inhibit PHA-stimulated incorporation of 3H-leucine into protein and 3H-uridine into RNA whether the drugs are added at the beginning of culture or 4 h prior to completion of 24-h cultures. There is no intracellular accumulation of 3H-thymidine, 3H-leucine, or 3H-uridine into 10% trichloroacetic acid-soluble molecules during inhibition with verapamil or isradipine, suggesting that these drugs impair the cellular uptake of these substances rather than directly inhibiting their incorporation into DNA, protein, or RNA, respectively. Since previous reports documenting the inhibitory effects of calcium channel blockers on lymphocyte proliferation have utilized 3H-thymidine incorporation into DNA to measure proliferation, we have re-examined the antiproliferative effects of these drugs by determining their effect on PHA-stimulated cell cycle progression, employing cytofluorometric analysis of propidium iodide-stained cells. When added at the initiation of culture, both verapamil and isradipine inhibited in a concentration-dependent manner PHA-stimulated cell cycle progression.(ABSTRACT TRUNCATED AT 250 WORDS)
先前已证明钙的跨膜通量在淋巴细胞激活中起重要作用。在此,我们证明钙通道阻滞剂维拉帕米和伊拉地平能够以浓度依赖的方式抑制3H-胸腺嘧啶核苷掺入植物血凝素(PHA)刺激的人外周血单核细胞(PBMC)的DNA中。然而,无论维拉帕米和伊拉地平是在培养开始时添加还是在72小时培养结束前4小时添加,它们将PHA刺激的胸腺嘧啶核苷掺入DNA的程度相同。因此,在维拉帕米或伊拉地平存在下3H-胸腺嘧啶核苷掺入DNA并不是有丝分裂原诱导的淋巴细胞增殖的有效测量方法。同样,无论药物是在培养开始时添加还是在24小时培养结束前4小时添加,维拉帕米和伊拉地平也抑制PHA刺激的3H-亮氨酸掺入蛋白质以及3H-尿苷掺入RNA。在用维拉帕米或伊拉地平抑制期间,没有3H-胸腺嘧啶核苷、3H-亮氨酸或3H-尿苷在10%三氯乙酸可溶分子中细胞内积累,这表明这些药物损害这些物质的细胞摄取,而不是分别直接抑制它们掺入DNA、蛋白质或RNA。由于先前记录钙通道阻滞剂对淋巴细胞增殖抑制作用的报告利用3H-胸腺嘧啶核苷掺入DNA来测量增殖,我们通过使用碘化丙啶染色细胞的细胞荧光分析确定它们对PHA刺激的细胞周期进程的影响,重新检查了这些药物的抗增殖作用。当在培养开始时添加时,维拉帕米和伊拉地平均以浓度依赖的方式抑制PHA刺激的细胞周期进程。(摘要截断于250字)